TY - JOUR
T1 - L-carnitine supplementation in duchenne muscular dystrophy steroid-naïve patients
T2 - A pilot study
AU - Escobar-Cedillo, Rosa E.
AU - Tintos-Hernández, Jesús A.
AU - Martińez-Castro, Guadalupe
AU - De Oca-Sańchez, Beatriz Montes
AU - Rodriǵuez-Jurado, Rodolfo
AU - Miranda-Duarte, Antonio
AU - Lona-Pimentel, Socorro
AU - Gómez-D́iaz, Benjamín
AU - Coral-Vázquez, Ramón M.
AU - Garciá, Silvia
AU - López Hernández, Luz Berenice
PY - 2013/8
Y1 - 2013/8
N2 - Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder characterized by progressive weakness leading to disability. Steroid administration and physiotherapy are the most useful medical interventions in ambulant patients; In DMD, muscles present a significant deficiency of L-carnitine compared to normal subjects. Nutritional supplements are used to support management. We evaluated the effect of L-carnitine supplementation in patients that were not under steroid treatment. A double blind, controlled trial was performed in 20 patients assigned to L-carnitine or placebo treatment for one year, dose of (50 mg/kg) twice daily. Evaluations were performed every 4 months and results were analyzed using ANOVA. Variables such as age, weight, and disease onset were similar in both groups. L-carnitine supplementation was well tolerated; no significant side effects were reported during and after treatment. Clinical evaluations showed no differences between groups (p>0.05). L-carnitine supplementation does not significantly improve the function of upper and lower extremities of DMD steroid-naïve patients.
AB - Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder characterized by progressive weakness leading to disability. Steroid administration and physiotherapy are the most useful medical interventions in ambulant patients; In DMD, muscles present a significant deficiency of L-carnitine compared to normal subjects. Nutritional supplements are used to support management. We evaluated the effect of L-carnitine supplementation in patients that were not under steroid treatment. A double blind, controlled trial was performed in 20 patients assigned to L-carnitine or placebo treatment for one year, dose of (50 mg/kg) twice daily. Evaluations were performed every 4 months and results were analyzed using ANOVA. Variables such as age, weight, and disease onset were similar in both groups. L-carnitine supplementation was well tolerated; no significant side effects were reported during and after treatment. Clinical evaluations showed no differences between groups (p>0.05). L-carnitine supplementation does not significantly improve the function of upper and lower extremities of DMD steroid-naïve patients.
KW - Clinical trial
KW - Duchenne muscular dystrophy
KW - L-carnitine supplementation
KW - Steroids
UR - http://www.scopus.com/inward/record.url?scp=84887374611&partnerID=8YFLogxK
M3 - Artículo
SN - 1540-7535
VL - 11
SP - 97
EP - 101
JO - Current Topics in Nutraceutical Research
JF - Current Topics in Nutraceutical Research
IS - 3
ER -